U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797115) titled 'Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes' on Jan. 22.
Brief Summary: Beyond their metabolic effect, SGLT-2 inhibitors reduce the risk of heart failure and have cardiovascular and nephroprotective effects, yet their exact mechanism of action remains unclear. This prospective study included 40 patients with type 2 diabetes whose physician initiated SGLT-2 inhibitor therapy. Prior to and after 4 weeks of the initiation of use of SGLT-2 inhibitors, in addition to routine clinical and laboratory measurements, hydroxyl free radical and neuropathic evaluations were performed.
Study Start Date: July ...